-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3100 Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, MDS, Clinical Research, bioinformatics, Chronic Myeloid Malignancies, Diseases, real-world evidence, Therapies, Myeloid Malignancies, Technology and Procedures
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Michael Pfeilstocker, Univ.-Prof., MD, MBA1,2, Heinz Tuechler3*, Lionel Ades4, Jaroslav Cermak, MD, PhD5, Fatiha Chermat6*, Matteo G. Della Porta, MD7*, Pierre Fenaux8, Guillermo Garcia-Manero, MD9, Ulrich Germing10*, Detlef Haase, MD, PhD11*, Andrea Kuendgen, MD12*, Michael Luebbert, MD13, Silvia Maria Meira Magalhaes, MD, PhD 14, Luca Malcovati, MD15,16, Yasushi Miyazaki, MD17, Guillermo Sanz, MD, PhD18,19,20,21, Valeria Santini, MD22, Mikkael A. Sekeres, MD23, Matthew J Walter, MD24,25, Peter Valent, MD2,26 and Peter L Greenberg, MD27

13rd Medical Department, Hematology & Oncology, Hanuschkrankenhaus, Vienna, Austria
2Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
33rd Med Dept, Hanusch Hospital, Vienna, Austria
4Department of Hematology and Bone Marrow Transplantation, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
5Dep. of Clinical Hematology, Inst. of Hematology & Blood Transfusion, Prague, Czech Republic
6Service d'Hématologie Séniors, Hôpital Saint-Louis, Paris, France
7Department of Biomedical Sciences, Humanitas University, Milan, Italy
8Université de Paris, Hematology department, Saint-Louis hospital, APHP, Paris, France
9University of Texas, MD Anderson Cancer Center, Houston, TX
10Dept. of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
11Clinics of Hematology and Medical Oncology, University Medicine Göttingen, Göttingen, Germany
12Heinrich Heine University, Department of Hematology, Oncology, and Clinical Immunology, Duesseldorf, Germany
13Clinic of Internal Medicine I, University Hospital Freiburg, Freiburg, Germany
14Department of Clinical Medicine; Cancer Cytogenomics Laboratory, Drug Research and Development Center, Universidade Federal do Ceará, Fortaleza, Brazil
15Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
16Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy
17Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
18CIBERONC, Instituto Carlos III, Madrid, Spain
19Istituto de Investigación Sanitaria La Fe, Valencia, Spain
20Hematology Deparment, Health Research Institute La Fe, Valencia, Spain
21Hematology Department, Hospital Universitario i Politècnic La Fe, Valencia, Spain
22DMSC, MDS Unit, AOU Careggi, University of Florence, Firenze, Italy
23Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
24Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO
25Washington University in St. Louis, St. Louis, MO
26Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
27Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA

Background

In MDS, most risk assessment tools such as the IPSS-R estimate risk at time of diagnosis. Risk assigned by the IPSS-R categories, however, is not constant over time. Changes in hazard (= time specific risk in a short time interval) during course of the disease affect the use of prognostic tools and may influence clinical decisions. We have previously shown time related hazard changes in untreated patients leading to declining risk in higher risk groups and diminution of differences between risk groups over time. Aim of this study was to investigate hazard changes in patients undergoing disease-modifying treatment.

Patients and methods

16 international partners of the IWG-PM contributed data from 9179 primary MDS patients of which 2015 had disease modifying treatment: median age 70.0 yrs, 60% male, median follow up 4.1 yrs, median OS 3.8 yrs, IPSS-R categories: very low 16%, low 35%, intermediate 22%, high 15%, very high 12%. Treatment modalities included hypomethylating agents, lenalidomide, cytotoxic therapy, 17% had stem cell transplantation. Time variations were described by smoothed hazard graphs and by the Cox zph test including rho, a measure for a linear time dependent impact of a feature on hazard. Semiparametric accelerated failure time models were estimated by direct optimization procedures.

Results and discussion

Using hazard graphs and the Cox zph-test we confirmed changes in hazard relations over time in the untreated subsample (rho -0.20 for OS). In treated patients a similar diminution was observed (rho -0.26 for OS). Results from treated patients revealed temporary increased hazard after some months especially in higher risk patients. Possible reasons are decision to start treatment when hazard increases or transient risk by therapy-associated toxicity, as well as a "guarantee time bias", induced by delayed treatment start, which in treated patients implicitly guarantees survival until start of treatment. To account for the latter, analyses were repeated excluding "guarantee time" in treated patients, again showing hazard reduction in higher risk patients and diminution between risk categories: untreated: rho -0.20 for OS, treated: rho -0.08 (fig A-B). Differently developing changes in hazards over time contradict the proportional hazards assumption of the Cox model. Therefore, as an alternative we investigated accelerated failure time models - fitting semi parametric models for IPSS-R risk categories: results show that patients in different risk categories share similar course of hazards - only at different "speeds" (speed-factors excluding guarantee time to achieve average survival: VERY LOW 0.34, LOW 0.63, INT 1.15, HIGH 2.23, VERY HIGH 5.11.) Transforming time accordingly makes common patterns visible, as in figure C, where most risk categories show hazard peaks before reaching the time of their median survival.

Conclusions

In MDS, hazards are not constant over time, possibly slightly rising until around the category specific median survival times and later clearly falling, except for the very high risk category. Longitudinal changes of hazards are not proportional between IPSS-R categories, instead diminution of hazard proportions between risk categories is observed. To describe the development of hazard for different IPSS-R categories the concept of different "speeds" of the disease development may be appropriate. Clinicians need to be aware of the dynamics of hazards in MDS when counselling patients both treated or those receiving supportive care only. Risk assessment at time of diagnosis by the IPSS-R assigns average group differences but changes over time need to be taken into account. Our data suggest that median survival times for IPSS-R categories approximately express different speeds and also indicate the time, when survival hazards are declining.

Disclosures: Pfeilstocker: BMS: Research Funding. Tuechler: BMS: Research Funding. Fenaux: AbbVie, BMS, Janssen, Jazz, Novartis: Consultancy, Honoraria, Research Funding. Garcia-Manero: Acceleron Pharma: Consultancy; Gilead Sciences: Research Funding; Aprea: Honoraria; AbbVie: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Astex: Consultancy, Honoraria, Research Funding; Curis: Honoraria, Research Funding; Genentech: Honoraria, Research Funding. Germing: Celgene: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria. Luebbert: AbbVie: Honoraria; Astex: Honoraria; Janssen: Research Funding; Otsuka: Consultancy; Syros: Consultancy; Cheplapharm: Other: study drug. Miyazaki: Daiichi-Sankyo: Honoraria; Takeda: Honoraria; Otsuka Pharmaceutical: Honoraria; Pfizer: Honoraria; Kyowa-Kirin: Honoraria; Bristol-Myers: Honoraria; Chugai: Honoraria; SyinBio: Honoraria; Dainippon-Sumitomo Pharma: Honoraria, Research Funding; Astellas: Honoraria; Abbvie: Honoraria; Novartis: Honoraria; Nippon Shinyaku: Honoraria; Janssen Pharmaceutical: Honoraria; Celgene: Honoraria. Sanz: takeda: Honoraria; Abbvie Pharmaceuticals: Other: Advisor or review panel participant; Helsinn: Honoraria, Other: Advisor or review panel participant; Novartis Oncology: Consultancy; Janssen Pharmaceuticals, Inc.: Other: Teaching and Speaking; Celgene Corporation: Consultancy; La Hoffman Roche Ltd.: Other: Advisor or review panel participant; Takeda Pharmaceuticals Ltd: Other: Advisor or review panel participant. Santini: BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Geron: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Menarini: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Otsuka: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Syros: Membership on an entity's Board of Directors or advisory committees. Sekeres: Bristol Myers-Squibb: Membership on an entity's Board of Directors or advisory committees; Kurome: Membership on an entity's Board of Directors or advisory committees; Takeda/Millenium: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Valent: Blueprint Medicines: Honoraria; Celgene: Honoraria, Research Funding; Novartis: Consultancy, Honoraria; Incyte: Honoraria.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH